

Formulary Update



Newfoundland and Labrador

Teva Canada is pleased to announce the following products are listed on the Newfoundland and Labrador Drug Formulary effective January 1, 2022.

Product Name	Strength	Size	Item Number	DIN
Octreotide for Injectable Suspension	10 mg	8mL, Vial	65409-0001	02503751
Octreotide for Injectable Suspension	20 mg	8mL, Vial	65410-0001	02503778
Octreotide for Injectable Suspension	30 mg	8mL, Vial	65411-0001	02503786

To obtain additional information, please contact your local Teva Canada Representative or Customer Care at 1.800.268.4129

TevaCanada.com